Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive factors and pharmacokinetics of intraperitoneal cisplatin and paclitaxel in stage III ovarian cancer
NL-OMON42305Phase 2Active, not recruiting
- Sponsor
- Medische Oncologie
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and paclitaxel in ovarian cancer, sponsored by Medische Oncologie. Primary endpoints: Patient data outcomes, Intraperitoneal immune cell phenotype and function and 4 more. Started Aug 2016; status: active, not recruiting.
02
Drugs
cisplatinpaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NL-OMON42305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42305.